Viking Therapeutics Completes $500 Million Upsized Offering
Viking Therapeutics announced that it completed an upsized equity and debt financing, raising gross proceeds of $575 million. The offering included the issuance of common stock and convertible senior notes. After accounting for underwriting discounts, commissions, and company expenses, Viking expects to receive net proceeds of approximately $547.8 million. The funds will likely be used to advance clinical development programs and support ongoing operations as a biopharmaceutical firm focused on metabolic diseases. The sizeable capital raise reflects investor confidence in the company's pipeline and long-term growth potential.
